KannaLife: Difference between revisions
Content deleted Content added
GreenC bot (talk | contribs) Rescued 1 archive link. Wayback Medic 2.5 |
linked word to be more understandable |
||
| Line 18: | Line 18: | ||
[[File:US-patent-6630507.pdf|thumb|right|KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent {{patent|US|6630507}} “Cannabinoids as Antioxidants and Neuroprotectants."]] |
[[File:US-patent-6630507.pdf|thumb|right|KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent {{patent|US|6630507}} “Cannabinoids as Antioxidants and Neuroprotectants."]] |
||
'''Kannalife Sciences Inc.''' is a bio-pharmaceutical and phyto-medical company based in [[Doylestown, Pennsylvania]] founded by Dean Petkanas and [[Thoma Kikis]].<ref>{{cite web |url=https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |archive-url=https://web.archive.org/web/20150508055419/https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |url-status=live |archive-date=May 8, 2015 |title=The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage |last=Guion |first=Payton |date=November 12, 2014 |work=VICE News |accessdate=2014-12-12 }}</ref> Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.<ref name="nyt1">{{cite web|url=https://www.nytimes.com/2014/11/02/nyregion/a-competition-to-get-a-medical-marijuana-license-in-new-york.html?_r=0|title=For Pot Inc., the Rush to Cash In Is Underway|last=Leland|first=John|date=October 31, 2014|work=The New York Times|accessdate=2014-10-31}}</ref> |
'''Kannalife Sciences Inc.''' is a bio-pharmaceutical and phyto-medical company based in [[Doylestown, Pennsylvania]] founded by Dean Petkanas and [[Thoma Kikis]].<ref>{{cite web |url=https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |archive-url=https://web.archive.org/web/20150508055419/https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |url-status=live |archive-date=May 8, 2015 |title=The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage |last=Guion |first=Payton |date=November 12, 2014 |work=VICE News |accessdate=2014-12-12 }}</ref> Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce [[oxidative stress]], and act as immuno-modulators and neuroprotectants.<ref name="nyt1">{{cite web|url=https://www.nytimes.com/2014/11/02/nyregion/a-competition-to-get-a-medical-marijuana-license-in-new-york.html?_r=0|title=For Pot Inc., the Rush to Cash In Is Underway|last=Leland|first=John|date=October 31, 2014|work=The New York Times|accessdate=2014-10-31}}</ref> |
||
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref> |
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref> |
||
Revision as of 08:26, 10 August 2020
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2010 |
| Founders | Dean Petkanas, Thoma Kikis |
| Headquarters | Doylestown, Pennsylvania |
| Total assets | Exclusive License of patent US 6630507 |
| Website | http://kannalife.com |
Kannalife Sciences Inc. is a bio-pharmaceutical and phyto-medical company based in Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis.[1] Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.[2]
In 2011, the company was granted an Exclusive License[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507, “Cannabinoids as Antioxidants and Neuroprotectants."[4]
Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[5] in Doylestown, PA, for a target drug candidate, KLS-13019[6] to treat Hepatic encephalopathy and CTE,[7] an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.
Kannalife was featured in Sports Illustrated article on using cannabinoids to treat CTE. [8]
References
- ^ Guion, Payton (November 12, 2014). "The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage". VICE News. Archived from the original on May 8, 2015. Retrieved 2014-12-12.
- ^ Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 2014-10-31.
- ^ "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
- ^ "Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
- ^ "Kannalife in R&D Collaboration for Cannabinoid-Based Drugs". Genengnews.com. Retrieved 2013-04-04.
- ^ William A. Kinney; Mark E. McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E. Brenneman. "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Med. Chem. Lett. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656.
- ^ Mulvihill Moran, Jessica (November 9, 2014). "Medical marijuana company developing drug to protect NFL players' brains". Fox News. Retrieved 2014-11-09.
- ^ "How cannabis is helping one company research treatment of CTE". Sports Illustrated. July 12, 2016.